Cyclo(RGD) peptide-decorated silver nanoparticles with anti-platelet potential for active platelet-rich thrombus targeting.

Abstract

The development of integrated nanomedicine for prevention and early diagnosis of thrombosis is highly significant. Platelet plays a vital role in thrombotic disorders, offering an ideal target for thromboprophylaxis and imaging of thrombi. We herein fabricated cyclo(RGD) peptide-decorated AgNPs (designated cRGD-AgNPs) for active targeting platelet-rich thrombi. In vitro cytotoxicity and hemolysis assays demonstrated that cRGD-AgNPs have acceptable biocompatibility pattern. Both PEG-AgNPs (non-targeted version) and cRGD-AgNPs can inhibit agonist-mediated platelet aggregation, whereas the latter exhibited significant attenuation on platelet activation and adhesion onto collagen and fibrinogen matrix. Furthermore, the superior binding ability of cRGD-AgNPs with platelet-rich thrombus was demonstrated in static/dynamic condition in vitro. In vivo studies revealed that cRGD-AgNPs could actively target thrombi in a mouse model of carotid artery thrombi with favorable safety. Our results here suggest that cRGD-AgNPs with intrinsic anti-platelet potential might be promising nano theranostics for thromboprophylaxis and active thrombus targeting.

• Authors: Yuanyuan Li, Yangye Jin, Xiaofeng He, Yonghui Tang, Min Zhou, Wenjing Guo, Wenjun Miao
• Journal: Nanomedicine : nanotechnology, biology, and medicine (Nanomedicine) Vol. 41 Pg. 102520 (04 2022) ISSN: 1549-9642 [Electronic] United States
• PMID: 35038589 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Anticoagulants
• Oligopeptides
• Silver

Topics

• Animals
• Anticoagulants
• Metal Nanoparticles (therapeutic use)
• Mice
• Oligopeptides (pharmacology)
• Silver (pharmacology)
• Thrombosis (drug therapy)
• Venous Thromboembolism